Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02296853 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02296853 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 20 participants.
The verdict
NCT02296853, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the single-dose pharmacokinetics of tenofovir alafenamide (TAF) and its metabolite tenofovir (TFV) in participants with normal hepatic function and in participants with severe hepatic impairment.
Interventions
- DRUG TAF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-12-22 |
| Est. Completion | 2015-04-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02296853
The ClinicalTrials.gov registry entry for NCT02296853 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAF is the first listed.
NCT02296853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02296853 about?
NCT02296853 is a clinical study titled "Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment". The primary objective of this study is to evaluate the single-dose pharmacokinetics of tenofovir alafenamide (TAF) and its metabolite tenofovir (TFV) in participants with normal hepatic function and in participants with severe hepatic impairment.
What is the current status of trial NCT02296853?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2014-12-22. Estimated completion is 2015-04-17.
What interventions are being tested in trial NCT02296853?
The interventions under investigation include: TAF (DRUG).
Who is sponsoring clinical trial NCT02296853?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.